ALK and non-small cell lung carcinoma: Moving to the neoadjuvant setting, Zhang et al. evaluated neoadjuvant crizotinib as feasible and well tolerated in 11 patients with resectable ALK-positive NSCLC, obtaining a partial response in 10 out of 11 patients and one stable disease.